Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R21 Clinical Trial Optional)
ID: 345341Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $275K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/345341

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-061.html
Timeline
  1. 1
    Forecast Posted Not available
  2. 2
    Forecast Due Not available
  3. 3
    Posted Jan 10, 2023, 12:00 AM UTC
  4. 4
    Due Jan 9, 2026, 12:00 AM UTC
Description

The National Institutes of Health (NIH) is inviting applications for the R21 Exploratory/Developmental Research Grant aimed at optimizing HIV prevention and care continuum outcomes. This funding opportunity encourages innovative research proposals that enhance understanding of the HIV prevention and care continuum, addressing barriers to access and effectiveness, with a focus on socio-economic disparities, treatment adherence, and HIV-related stigma. The total funding amount is capped at $275,000 over a two-year period, with applications due by January 9, 2026. Interested applicants can find more information and submit inquiries via email at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-23-061.html.

Point(s) of Contact
grantsinfo@nih.gov
Files
Title
Posted
PAR-23-061-Full-Announcement.html
Aug 24, 2024, 2:22 AM UTC
PAR-23-061.html
Aug 24, 2024, 2:22 AM UTC
The Department of Health and Human Services, through the National Institutes of Health (NIH), is soliciting applications for the R21 Exploratory/Developmental Research Grant aimed at optimizing HIV prevention and care outcomes. This funding opportunity encourages innovative research proposals that enhance understanding of the HIV prevention and care continuum, addressing key barriers to access and effectiveness. The grant focuses on diverse approaches to HIV testing, treatment adherence, and retention in care, highlighting the importance of community engagement and multi-level interventions. Key objectives include addressing socio-economic disparities, improving adherence to treatment, and understanding the factors influencing HIV-related stigma. Various application types are permitted, and projects should aim for practical implications and scalability. The total budget is capped at $275,000 over two years, with multiple submission deadlines. This initiative aligns with national and global health goals, notably the U.S. National HIV/AIDS Strategy, which aims for significant reductions in HIV transmission through comprehensive care and prevention strategies. Proposals are encouraged from a wide range of organizations, including minority-serving institutions, emphasizing collaborative and innovative approaches to HIV research.
Similar Opportunities
Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R01 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) is inviting applications for the funding opportunity titled "Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R01 Clinical Trial Optional)" under the National Institute of Mental Health (NIMH). This initiative aims to support innovative research focused on optimizing HIV prevention and care, emphasizing the understanding of behavioral and social science factors that influence the HIV continuum, including intervention efficacy trials and implementation science studies. The program is critical for advancing national efforts to address HIV effectively, promoting community engagement and multidisciplinary collaboration to achieve equitable health outcomes for diverse populations. Interested applicants can find more information and application details at the provided link, with a submission deadline of January 9, 2026, and no cost-sharing or matching requirements.
Formative and Pilot Intervention Research to Optimize HIV Prevention and Care Continuum Outcomes (R34 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity titled "Formative and Pilot Intervention Research to Optimize HIV Prevention and Care Continuum Outcomes (R34 Clinical Trial Optional)." This initiative aims to support formative research and pilot-testing of interventions designed to enhance HIV prevention and treatment outcomes, particularly focusing on innovative strategies that address mental health, social determinants, and structural factors affecting HIV care. The funding opportunity is crucial for developing effective HIV testing and treatment linkage strategies, ultimately contributing to national goals in HIV management and reducing health disparities among affected populations. Eligible applicants can receive direct costs up to $225,000 per year for a project duration not exceeding three years, with applications due by January 9, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-060.html.
Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of NIDDK (R21 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) is inviting applications for the grant opportunity titled "Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of NIDDK." This funding initiative aims to support innovative pilot research projects that explore the biological, behavioral, and social mechanisms related to HIV pathogenesis, particularly focusing on comorbidities and complications affecting organs and tissues relevant to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The research is expected to enhance understanding of the interplay between HIV and associated health issues, with a funding cap of $275,000 over two years for successful applications. Interested applicants, including higher education institutions and various nonprofit organizations, should note that the application deadlines begin in April 2025, with the final submission date set for January 7, 2028. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
Development and Testing of Novel Interventions to Improve HIV Prevention, Treatment, and Program Implementation for People Who Use Substances (R34 Clinical Trial Required)
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity titled "Development and Testing of Novel Interventions to Improve HIV Prevention, Treatment, and Program Implementation for People Who Use Substances" under the R34 planning grant mechanism. This initiative aims to encourage formative research and the development of innovative interventions that target HIV prevention and care, particularly for populations that engage in substance use, addressing critical gaps in HIV care and prevention. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofit entities, and tribal governments, with grants available for up to $450,000 over three years. The application cycle begins on April 7, 2025, with subsequent due dates throughout the year, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
Innovation for HIV Vaccine Discovery (R01 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) is offering a grant opportunity titled "Innovation for HIV Vaccine Discovery" (NOFO Number PAR-23-169) aimed at supporting high-risk, high-impact early discovery research focused on innovative vaccine approaches to prevent HIV acquisition and ongoing infection. This initiative emphasizes a Go/No-Go funding approach, requiring applicants to demonstrate measurable progress towards defined goals by the end of Year 2, with continued funding contingent upon meeting these criteria. The overall budget for this initiative is approximately $2 million for fiscal year 2024, with individual project budgets capped at $350,000 per year, and applications must be submitted via Grants.gov by August 2, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
Opportunities for HIV Cure Strategies at the Time of ART Initiation (R21 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) has announced a funding opportunity aimed at exploring innovative HIV cure strategies at the initiation of combination antiretroviral therapy (cART). This initiative seeks to identify and develop interventions that can be applied at the start of cART or following treatment interruptions, with the ultimate goal of achieving sustained treatment-free remission. The funding, available for up to two years with a maximum budget of $275,000, is open to a diverse range of eligible applicants, including higher education institutions, non-profits, and for-profit entities. Interested parties can find more information and application guidelines at the NIH grants website, with a submission deadline set for September 7, 2026.
Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH), through its National Institute on Deafness and Other Communication Disorders (NIDCD), has announced a funding opportunity titled "Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional)." This grant aims to stimulate innovative research addressing critical issues related to communication disorders—such as hearing, balance, taste, smell, voice, speech, and language—specifically for individuals living with HIV/AIDS. The initiative encourages multidisciplinary collaborations and supports low-risk clinical trials that do not require FDA oversight, with a total funding limit of $275,000 for two-year projects, and no more than $200,000 in any single year. Interested applicants, including various academic institutions and nonprofits, must submit their proposals by January 7, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity for research initiatives focused on HIV-associated non-communicable diseases (NCDs) at low- and middle-income country (LMIC) institutions through the R21 Clinical Trial Optional grant. This program aims to support locally relevant research that explores the relationship between HIV infection and the development of NCDs, enhance research capacity, and foster collaborative networks among researchers in LMICs and the U.S. The grant provides funding up to $275,000 over a two-year period, with a submission deadline of December 8, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) has announced a funding opportunity titled "Multidisciplinary Studies of HIV/AIDS and Aging," aimed at exploring the intersection of HIV and aging. This initiative seeks to enhance understanding of the biological, clinical, and socio-behavioral aspects of aging in the context of HIV infection, while also improving strategies for testing, prevention, and treatment of HIV-related health complications. Given the increasing number of older adults living with HIV, this research is crucial for addressing public health challenges and improving healthcare delivery across diverse populations. The funding supports exploratory research under the R21 mechanism, with a maximum budget of $275,000 for two years, and applications are due between May 2025 and January 2027. For more information, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-355.html.
High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)" aimed at supporting innovative research that addresses the intersection of HIV and substance use. This initiative invites applications from individual researchers and research teams to develop projects that can lead to new prevention, treatment, and care strategies for individuals affected by both conditions, with a requirement for a detailed research plan and preliminary data. A total budget of $3.0 million is available for funding one to two awards, with individual project budgets capped at $1.5 million per fiscal year, and applications are due by February 12, 2027. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to consult with NIDA program staff early in the application process.